RenovoRx Inc
RNXT1.210USD
0.000
Market hours （ET）Quotes delayed by 15 min
44.22MMarket Cap
LossP/E TTM
More Details of RenovoRx Inc Company
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Company Info
Ticker SymbolRNXT
Company nameRenovoRx Inc
IPO dateAug 17, 2021
CEOMr. Shaun R. Bagai
Number of employees10
Security typeOrdinary Share
Fiscal year-endAug 17
Address2570 W. El Camino Real, Ste. 320,
CityMOUNTAIN VIEW
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94040
Phone14088002649
Websitehttps://renovorx.com/
Ticker SymbolRNXT
IPO dateAug 17, 2021
CEOMr. Shaun R. Bagai
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
10.42%
Private Equity
7.09%
Investment Advisor
5.92%
Individual Investor
4.42%
Hedge Fund
3.79%
Bank and Trust
0.27%
Venture Capital
0.06%
Other
68.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
51
11.69M
31.97%
+5.32M
2025Q1
52
10.53M
29.46%
+6.73M
2024Q4
39
1.47M
4.14%
-2.25M
2024Q3
38
2.35M
9.16%
-392.19K
2024Q2
40
2.34M
14.23%
-1.80M
2024Q1
36
1.98M
17.38%
-1.99M
2023Q4
40
1.81M
16.91%
-1.93M
2023Q3
39
3.15M
32.01%
-2.10M
2023Q2
36
3.04M
31.03%
-2.11M
2023Q1
36
5.01M
55.46%
+3.39M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AIGH Capital Management, LLC.
2.59M
7.09%
+2.59M
--
Mar 31, 2025
AWM Investment Company, Inc.
2.29M
6.25%
+2.29M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.35M
3.68%
+1.20M
+851.09%
Mar 31, 2025
Agah (Ramtin M.D.)
1.13M
3.1%
+21.00K
+1.89%
Jun 05, 2025
Worth Venture Partners, LLC
873.61K
2.39%
+873.61K
--
Mar 31, 2025
Alyeska Investment Group, L.P.
688.58K
1.88%
+688.58K
--
Mar 31, 2025
Bleichroeder LP
500.00K
1.37%
+500.00K
--
Mar 31, 2025
Adar1 Capital Management LLC
479.88K
1.31%
+282.63K
+143.29%
Mar 31, 2025
Geode Capital Management, L.L.C.
321.87K
0.88%
+86.13K
+36.53%
Mar 31, 2025
Bagai (Shaun R.)
320.04K
0.88%
+27.50K
+9.40%
Apr 25, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
